Photo - Startup 64728
64728

TriasBio

USA, California
Market: Biotech
Project stage: Prototype or product is ready
 
Also this project:
- Participate in the Unicorn Battle

Idea or High Level Concept

Your body runs on a 24-hour clock. Your medicines don't. TriasBio is changing that - designing RNA therapeutics that harness the biological clock for maximum efficacy and minimum toxicity.

Traction and Current Status

Revenue within 6 months of launch, 4 paying customers, validated in 8 therapeutic areas. 163K downloads of our public AI model. Patent pending. Awards from Genentech and Amgen and others.

Problem or Opportunity

80% of drugs fail in the clinic due to low efficacy or high toxicity. Yet medicines are designed as if the body were the same at 8am and 8pm. It isn’t: more than half of top-selling drugs hit targets that rise and fall over the day. Ignoring the body’s clock leaves efficacy on the table and drives side effects.

Solution

TriasBio is changing that by designing intelligent RNA therapeutics that work with the body's internal clock. At the core is our proprietary large language model (LLM) platform, trained to design RNA sequences. We're teaching our models a new dimension the whole industry is missing: time. The result is medicines that are active when their target is present and side effects are lowest.

Business Model, Chanells, Metrics

Customers pay per sequence for AI design today, then move to annual subscriptions. Licensing our circadian technology into partners’ drugs adds upfronts, milestones and royalties. Longer term, our platform and proprietary circadian factors open the door to developing our own time-optimized therapeutics.

Incubation/Acceleration programs accomplishment

Nucleate Activator, Berkeley Skydeck Pad13, Baker Labs QB3 mentoring, NVIDIA Inception
arrow_back
EN